Dossier
Wainua
Coverage of Wainua in the Nexus archive.
- AstraZeneca stock plunges after late-stage heart drug trial misses its target
AstraZeneca's stock fell sharply after its late-stage heart drug trial for Wainua failed to reduce cardiovascular deaths and recurring heart events, causing a $27 billion drop in market value.
- STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis Pharmaceuticals reported that their heart disease drug, Wainua, failed in a pivotal trial for ATTR-CM, showing no improvement over placebo in reducing cardiovascular death and clinical events. The failure caused AstraZeneca's U.S. shares to drop 8% and London-listed shares to fall 9%, while Ionis shares fell 12%.